CMS has advised Egis Pharmaceuticals on its acquisition of a dermatological product line from Teva Pharmaceutical Industries. Bird & Bird reportedly Teva.
According to CMS, "the acquisition holds strategic significance for Egis, a Hungary-based pharmaceutical company with a legacy spanning over 110 years. This move aims to solidify its position in the Hungarian over-the-counter market while expanding its portfolio of locally applied dermatological products."
The CMS team included Partners Eszter Torok, Dora Petranyi, and Szabolcs Szendro, Senior Counsel Veronika Kovacs, and Senior Associates Aranka Nagy and Miklos Boros.
The Bird & Bird team included Partners Pal Szabo and Balint Halasz, Senior Counsel Ferenc Matrai, Counsel Daria Szabo, and Associate, Adel Gelencser.
